Atlas Trials

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Clinical trial NCT01871675 · COMPLETED

Trial details

NCT number
NCT01871675
Sponsor
SCRI Development Innovations, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin LymphomaT-cell Lymphoma
Start date
2013-05-01
Primary completion
2016-06-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.